WDR82 CRISPR Activation Plasmid (h): sc-406963-ACT

WDR82 (WD repeat domain 82) encodes a WD40 repeat–containing protein that functions as a chromatin-associated regulatory factor linking transcription with RNA processing. It has been implicated in promoter-proximal control of gene expression and coordination of histone modification states through interactions with nuclear protein complexes that shape transcriptional output. Through these roles, WDR82 can influence pathways governing cell cycle progression, genome stability, and stress-responsive transcriptional programs. Dysregulated expression or altered function of WDR82 has been reported across multiple cancer and developmental biology contexts, supporting its utility as a target for mechanistic studies of epigenetic regulation and transcriptional control.

WDR82 CRISPR Activation Plasmid (h) provides a targeted, non-destructive approach to upregulating endogenous WDR82 expression without altering the underlying DNA sequence.

WDR82 CRISPR Activation Plasmid (h) is a three-plasmid synergistic activation mediator (SAM) system engineered for highly efficient, site-specific transcriptional upregulation of the WDR82 locus in human cell lines. The system is built around a catalytically inactive Cas9 (dCas9) carrying two inactivating mutations (D10A and N863A) that eliminate nuclease activity while preserving DNA binding. This dCas9 is fused to VP64, a potent transcriptional activator, and is co-expressed with a blasticidin resistance gene for selection. The second plasmid encodes the MS2-p65-HSF1 fusion protein, a secondary activator complex that works in concert with dCas9-VP64, alongside a hygromycin resistance gene. The third plasmid encodes a target-specific 20 nt sgRNA fused to two MS2 RNA aptamers that recruit the MS2-p65-HSF1 complex to the activation site, accompanied by a puromycin resistance gene. The three plasmids are delivered at a 1:1:1 mass ratio for balanced expression of all system components.

Once assembled at the target locus, the SAM complex binds within approximately 200 bp upstream of the WDR82 transcriptional start site, where VP64, p65, and HSF1 act in concert to recruit transcriptional machinery and drive upregulation of endogenous WDR82 expression. Unlike nuclease-active Cas9, dCas9 does not introduce double-strand breaks or modify the genomic sequence, preserving the native WDR82 locus and enabling the study of WDR82-dependent transcriptional responses at the endogenous locus, making it a valuable tool for functional studies, target gene identification, and the modeling of WDR82 pathway restoration in tumor cells with silenced or reduced WDR82 expression.

For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.